ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Form 8-K — Jun 16, 2026
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a new director effective June 12, 2026. Dr. Cohen brings over 25 years of experience in healthcare investing and portfolio management to the board.
Key figures
- Vesting Period
- 3 years
- Sign On Grant Value
- $887,000
Price after filing
1 day: +5.9%7 days: +4.4%30 days: -6.2%
Close on the filing date to close N calendar days later (from $76.55). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.